ADHD Smoking Cessation Study - NCT00736255-27705 (Clinical Trial 236965)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy236965.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Durham |
|
State:
|
|
NC |
| Zip Code: |
|
27705 |
| Conditions: |
|
Attention Deficit Hyperactivity Disorder - Nicotine Dependence |
| Purpose: |
|
The overall goal of the present project is to investigate whether lisdexamphetamine (LDX;
Vyvanse) is an effective adjunct to nicotine replacement therapy (NRT) to promote smoking
cessation in patients with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and
nicotine dependence. The investigators hypothesized initially that smokers with ADHD who
are optimized to a dose of LDX prior to quitting smoking and who remain on this dose of
medication after quitting will remain abstinent longer than patients who are treated with
placebo before and after quitting.However due to recent key issues that have arisen showing
that initiation of stimulant treatment while subjects are actively smoking may facilitate
increased smoking, and given that the study was still in the very early stage of study
execution, the investigators revised the study design to use an empirically validated
pretreatment approach with NRT and to initiate LDX treatment on the first post quit date in
order to reduce the withdrawal symptoms that accompany smoking cessation. The overall
rationale for this revised study design remains similar to the original.
|
| Study summary: |
|
This will be a 2-group, parallel, placebo-controlled, double blind study. Regular, nicotine
dependent individuals with ADHD will receive NRT pretreatment for 2 weeks prior to an
identified quit date.At the quit date, subjects will be randomized into one of two groups.
- The first group will begin treatment for 1 week with LDX 30 mg and then will be
titrated up to 50mg and 70mg if tolerated. Subjects will continue on the highest
tolerated dose until the 4th week. Concurrently subjects will receive transdermal NRT,
21 mg at week one, 14 mg at week 2 and 7 mg at weeks 3 and 4.
- The second group will receive matching placebo and transdermal NRT after the quit date.
Participants will attend a total of 16 visits over a period of 7-11 weeks. The primary
outcome measure for this study will be the proportion of individuals in each group who
report 4 weeks continuous smoking abstinence verified by both CO levels and salivary
cotinine, measured at Visit 5. It is hypothesized that the group co-treated with LDX will
have a significantly higher proportion of individuals who remain abstinent across the 4
weeks measured every other day.
Inclusion Criteria:
- Aged 18-50 years
- Meet DSM-IV criteria for ADHD, any subtype; assessed using the Conners Adult ADHD
Interview for DSM (CAADID
- Meet DSM-IV criteria for nicotine dependence as verified by afternoon expired CO levels
of >15 ppm and self-report of smoking >10 cigarettes/day
- Free from major medical problems and deemed healthy by the study physician
- Not currently receiving medication for ADHD or other psychiatric disorders. If a
patient is screened as is currently receiving medication for ADHD, they may be
enrolled, provided they washout of their current medication for an appropriate length
of time.
- No contraindications for treatment with either LDX or transdermal nicotine
Exclusion Criteria:
- DSM-IV Axis I or Axis II disorders that require additional pharmacological treatment or
otherwise would interfere with participation in the present study
- History of known cardiovascular disease, clinically significant hypertension, or other
cardiovascular risk factors which, in the opinion of the study physician, would
contraindicate treatment
- BMI > 35 |
| Criteria: |
|
Inclusion Criteria:
- ADHD diagnosis
- smokes at least > 10 cigarettes per day
- no major medical problems
- no contraindications to treatment with either LDX or transdermal nicotine
Exclusion Criteria:
- other psychiatric conditions that require medication
- history of cardiovascular disease, clinically significant hypertension
- BMI > 35 |
|
|
|
| Study is available at: |
|
Duke ADHD Program
Durham, NC 27705
United States
Primary Contact:
Nilda Itchon-Ramos, BS
Email: itcho001@mc.duke.edu
Phone: 919-416-2083 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|